MS: Busting the Myths
February 24, 2025 | Advocacy, News
Recently, Multiple Sclerosis New Zealand (MSNZ) wrote to Pharmac to express our immense disappointment with their Health Technologies Assessment (HTA) process, the treatment funding assessment process, and the impact this is having on the MS community. The varicella zoster virus, […]
May 30, 2024 | Advocacy, Treatments
At MSNZ we would like to understand more about patient experiences with infusion treatments. The first line Disease Modifying Treatment (DMT) options we have been successful in advocating for in NZ are considered some of the best in the world. […]
May 15, 2024 | Advocacy, Funding, Life with MS, Media, News, Press Release, Treatments
A celebrated Pharmac decision late last year to fund a vital drug for many Multiple Sclerosis patients has fallen flat – with dozens being turned away for treatment due to severely stretched resources across a number of services. Multiple Sclerosis […]
April 30, 2024 | Advocacy, Funding, Life with MS
On Monday 18 March 2024, Whaikaha – Ministry of Disabled People, announced changes to the purchasing rules for Carer Support, Individualised Funding, Enhanced Individualised Funding, personal budgets, and Choices in Community Living. On 24 April, following significant feedback from the […]
April 29, 2024 | Advocacy, Aids, Funding, Life with MS, My Story
Sativex, or Cannabidiol with tetrahydrocannabinol, is an add-on treatment approved by Medsafe for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (MS). It is indicated for people who have not responded adequately to other anti-spasticity […]